Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 29;5(2):41-47.
doi: 10.1016/j.ncrna.2020.02.005. eCollection 2020 Jun.

Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?

Joseph Nader  1 , Laurent Metzinger  2 , Pierre Maitrias  3 , Thierry Caus  1 , Valérie Metzinger-Le Meuth  2   4
Affiliations
Review

Aortic valve calcification in the era of non-coding RNAs: The revolution to come in aortic stenosis management?

Joseph Nader et al. Noncoding RNA Res. .

Erratum in

Abstract

Aortic valve stenosis remains the most frequent structural heart disease, especially in the elderly. During the last decade, we noticed an important consideration and a huge number of publications related to the medical and surgical treatment of this disease. However, the molecular aspect of this degenerative issue has also been more widely studied recently. As evidenced in oncologic but also cardiac research fields, the emergence of microRNAs in the molecular screening and follow-up makes them potential biomarkers in the future, for the diagnosis, follow-up and treatment of aortic stenosis. Herein, we present a review on the implication of microRNAs in the aortic valve disease management. After listing and describing the main miRNAs of interest in the field, we provide an outline to develop miRNAs as innovative biomarkers and innovative therapeutic strategies, and describe a groundbreaking pre-clinical study using inhibitors of miR-34a in a pre-clinical model of aortic valve stenosis.

Keywords: Aortic stenosis; Biomarker; Translational research; microRNA.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Molecular aspects of aortic valve calcification, showing the major main process implicated in the aortic valve calcifications.
Fig. 2
Fig. 2
An outline to develop miRNAs as new biomarkers and innovative treatments in the field of valve calcification. Total RNA can be extracted from cell cultures, pre-clinical models. Up to a thousand miRNA expression can be titrated using either transcriptomics (eg. Microarray, next generation sequencing …) to detect the most deregulated miRNAs. These miRNAs can then be measured in patient cohorts to validate them as diagnostic or prognostic biomarkers. In long term up-of down-regulating their expression in selective tissues can be a new therapeutic approach.
See this image and copyright information in PMC

References

    1. Cribier A., Eltchaninoff H., Bash A., Borenstein N., Tron C., Bauer F. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002;106(24):3006–3008. - PubMed
    1. Popma J.J., Deeb G.M., Yakubov S.J., Mumtaz M., Gada H., O'Hair D. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N. Engl. J. Med. 2019;380(18):1706–1715. - PubMed
    1. Mack M.J., Leon M.B., Thourani V.H., Makkar R., Kodali S.K., Russo M. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N. Engl. J. Med. 2019;380(18):1695–1705. - PubMed
    1. Otto C.M. Calcific aortic stenosis--time to look more closely at the valve. N. Engl. J. Med. 2008;359(13):1395–1398. - PubMed
    1. Braverman A.C., Guven H., Beardslee M.A., Makan M., Kates A.M., Moon M.R. The bicuspid aortic valve. Curr. Probl. Cardiol. 2005;30(9):470–522. - PubMed

LinkOut - more resources